{"version":"1.0","type":"link","title":"Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+/ISH+ and HER2 3+ in HER2-Positive Breast Cancer.","author_name":"Ma L 외","author_url":"https://prs-insight.online/author/Ma%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/79149","thumbnail_width":1200,"thumbnail_height":630}